Kosabio, a company specializing in pharmaceutical and pharmacological research and development, announced on May 2 that it is accelerating its entry into the global bio market through the registration of a U.S. patent and selection for a government project. Kosabio is a company that has signed a business agreement with DYD.
The newly registered U.S. patent covers a technology for the prevention and treatment of male climacteric syndrome (Testosterone Deficiency Syndrome, TDS) using the active ingredient 'KSB191' derived from elderberry. With this patent registration, Kosabio has secured key intellectual property rights in major markets including Korea, Japan, China, Europe, and now the United States.
KSB191 is a novel functional material that restores mitochondrial function in Leydig cells and promotes testosterone secretion. Kosabio has completed human application trials for this material and is preparing to obtain recognition as a functional ingredient for health functional foods in Korea. Based on these achievements, the company plans to actively enter the male climacteric and slow-aging markets.
Kosabio has completed human application trials for KSB191 candidate substances related to individually recognized functional ingredients for improving male climacteric symptoms. The trial was conducted over 12 weeks on men aged 40 to 65 experiencing climacteric symptoms, and significant improvements were observed in key indicators related to male climacteric syndrome.
In addition, the company was selected for the bio sector in the "2025 SME Technology Innovation Development Project: Market Response Type" under the growth engine advancement category. This research aims to develop functional ingredients to improve diseases related to sarcopenia and muscle weakness.
Through KSB191, which includes the core active substance sugar-amino acid complex (MS2A), Kosabio will clarify the relationships between hormone regulation, muscle strength improvement, and mitochondrial recovery and enhancement, and will conduct human application trials. The total project budget is 640 million won, of which 480 million won, or 75%, will be supported by the government over two years.
Meanwhile, on April 24, Kosabio signed a memorandum of understanding (MOU) with DYD and Yeoncheon-gun for the localization and commercialization of elderberry-based functional materials. DYD will strategically support stable raw material procurement, functional product manufacturing, and domestic and international market distribution. Both companies aim to jointly expand in the biohealth sector.
Park Hyunseok, CEO of Kosabio, stated, "We are expanding the functionality of KSB191 beyond improving male climacteric symptoms to include muscle strength enhancement," adding, "Based on our collaboration with DYD, we will accelerate our entry into the global bio market and the development of various functional products."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
